Abstract
Background SARS-CoV-2 infection may lead to Post-COVID Syndrome (PCS), characterized by debilitating symptoms like persistent fatigue, cardiovascular symptoms, and cognitive dysfunction. Persistent endothelial dysfunction (ED) is a potential driver of ongoing symptoms. Yet, the underlying biological mechanisms remain unclear.
Methods In this prospective observational study, we characterized 41 PCS patients and 24 healthy controls (HC, matched out of n = 204, recruited before the pandemic) and investigated the effect of SARS-CoV-2 Spike protein 1 (S1) and plasma from PCS patients on human retinal endothelial cells (HREC).
Results Plasma samples from PCS patients exhibited significantly elevated erythropoietin, VEGF and MCP-1 alongside decreased IL-6 levels compared to HC. Low Haemoglobin and Haematocrit were negatively associated with PCS severity. VEGF levels were positively correlated with Anti-S1 IgG levels in patients and upregulated on mRNA level in HREC exposed to S1. Additionally, S1 exposure promoted ROS production and transiently activated HIF-1α in HREC. Persistent activation of HIF-2α by S1 led to disrupted endothelial integrity. HREC exposed to plasma from severely affected PCS patients showed increased ROS and compromised barrier function. Treatment with Belzutifan, a HIF-2α inhibitor, restored barrier integrity in HREC exposed to S1 or PCS-plasma.
Conclusion These findings suggest that HIF-2α-mediated ED in PCS might be a potential therapeutical target for Belzutifan.
Trial registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT05635552
What Is Known?
Endothelial dysfunction (ED) is a consequence of acute SARS-CoV-2 infection and may lead to Post-COVID syndrome (PCS) symptoms.
Patients with PCS show elevated inflammation and endothelial dysfunction markers.
Spike proteins can persist for up to 12 months post-infection, driving ongoing inflammation and immune activation.
What New Information Does This Article Contribute?
Low haemoglobin (Hb) and high VEGF correlate with higher Anti-S1 IgG and low Hb is associated with higher C19-YRS severity score.
PCS patients exhibit higher Erythropoietin (EPO) levels when compared to HC.
Spike protein 1 (S1) alone and PCS patient’s plasma induce endothelial dysfunction primarily through HIF-2α activation.
Both S1 and PCS plasma cause oxidative stress and disrupting endothelial integrity.
Inhibition of HIF-2α effectively restores endothelial barrier integrity disrupted by S1 and PCS plasma.
What New Information Does This Article Contribute?Persistent circulation of spike proteins can sustain chronic inflammation and immune activation in patients with PCS. Here we show that plasma from PCS patients exhibits significantly elevated levels of VEGF which positively correlates with Anti-S1 IgG. Low haemoglobin was associated with higher Anti-S1 IgG titres and correlated with a higher C19-YRS severity score. Levels of EPO were higher in PCS patients, with a more pronounced effect observed in patients with cardiovascular symptoms. In human retinal endothelial cells, both S1 and plasma from PCS patients primarily induce ED through HIF-2α activation, rather than NF-κB. Both factors lead to significant oxidative stress, evidenced by increased ROS production which in turn disrupts endothelial barrier integrity and function. Notably, Belzutifan, a HIF-2α inhibitor, can restore this compromised endothelial function, offering a potential therapeutic target for PCS.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/38041762/
Funding Statement
This study is sponsored by the Bavarian State Ministry of Science and Art, as part of its Special Funding Program for the Scientific Coronavirus Research Projects of the Technical University of Munich School of Medicine at the University Medical Center Rechts der Isar (Funding Identification Number H.4001.1.7-53/7).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the local ethics committee (Ethics Committee of the Technical University of Munich, School of Medicine, Klinikum rechts der Isar; Approval number: 2022-317-S-SR) and was previously registered (https://clinicaltrials.gov/ct2/show/NCT05635552). All participants in this study provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Nonstandard Abbreviations and Acronyms
- ACE2
- angiotensin-converting enzyme-2
- C19-YRS
- COVID-19 Yorkshire Rehabilitation Scale
- CoCl2
- Cobalt chloride
- CXCL1
- C-X-C motif chemokine ligand 1
- CXCL10
- C-X-C motif chemokine ligand 10
- EC
- Endothelial cells
- ECIS
- Electrical cell-substrate impedance sensing
- ED
- Endothelial dysfunction
- EPO
- Erythropoietin
- FSS
- Fatigue Severity Scale
- Hb
- Hemoglobin
- HC
- Healthy control
- Hct
- Hematocrit
- HIF
- Hypoxia inducible factor
- HREC
- Human retinal endothelial cells
- ICAM-1
- Intercellular adhesion molecule 1
- IL-6
- Interleukin-6
- IL-8
- Interleukin 8
- LPS
- Lipopolysaccharide
- MCP-1
- Monocyte Chemoattractant Protein-1
- ME/CFS
- Myalgic encephalomyelitis/chronic fatigue syndrome
- Nrf2
- NF-E2-related factor
- NO
- Nitric oxide
- PCS
- Post-COVID Syndrome
- PHQ-9
- Patient Health Questionnaire 9
- PROM
- Patient reported-outcome measures
- ROS
- Reactive oxygen species
- RT-PCR
- Reverse transcription-polymerase chain reaction
- S1
- Spike protein 1
- SARS-CoV-2
- Severe-Acute-Respiratory-Syndrome Coronavirus 2
- SD
- Standard deviation
- TEER
- Transendothelial electric resistance
- TNF
- Tumor necrosis factor
- VEGF
- Vascular endothelial growth factor
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.